The regulation of S6K by 3-phosphoinositide dependent protein kinase-1 (PDK-1) may explain the difference in inhibition of p-mTOR and p-S6 status as demonstrated after rapamycin treatment in urothelial carcinoma [24, 25]. The gene discussed is MTOR; the disease is urothelial carcinoma.